Leptin regulates body weight, reproductive functions, blood pressure, endothelial function, and fetoplacental angiogenesis. Compared to the luteal phase, the follicular phase and pregnancy are physiological states of elevated estrogen, angiogenesis, and uterine blood flow (UBF). Little is known concerning regulation of uterine artery (UA) angiogenesis by leptin and its receptors. We hypothesized that (1) ex vivo expression of leptin receptors (LEPR) in UA endothelium (UAendo) and UA vascular smooth muscle (UAvsm) is elevated in pregnant versus nonpregnant (Luteal and Follicular) sheep; (2) in vitro leptin treatments differentially modulate mitogenesis in uterine artery endothelial cells from pregnant (P-UAECs) more than in nonpregnant (NP-UAECs) ewes; and (3) LEPR are upregulated in P-UAECs versus NP-UAECs in association with leptin activation of phospho-STAT3 signaling. Local UA adaptations were evaluated using a unilateral pregnant sheep model where prebreeding uterine horn isolation (nongravid) restricted gravidity to one horn. Immunolocalization revealed LEPR in UAendo and UAvsm from pregnant and nonpregnant sheep. Contrary to our hypothesis, western analysis revealed that follicular UAendo and UAvsm LEPR were greater than luteal, nongravid, gravid, and control pregnant. Compared to pregnant groups, LEPR were elevated in renal artery endothelium of follicular and luteal sheep. Leptin treatment significantly increased mitogenesis in follicular phase NP-UAECs and P-UAECs, but not luteal phase NP-UAECs. Although UAEC expression of LEPR was similar between groups, leptin treatment only activated phospho-STAT3 in follicular NP-UAECs and P-UAECs. Thus, leptin may play an angiogenic role particularly in preparation for the increased UBF during the periovulatory period and subsequently to meet the demands of the growing fetus.
Introduction
Leptin is an adipocyte-derived hormone that regulates nutritional status [1] , body weight [2, 3] , and reproductive processes [4] collectively contributing to the control of cardiovascular function, blood pressure regulation, vascular permeability, endothelial function, vascular compliance, and angiogenesis [5] [6] [7] [8] [9] . Furthermore, leptin is secreted into both fetal and maternal circulations in the human [10] and sheep placenta [11, 12] . Leptin's exact role in the local maternal vascular compartment during pregnancy and preeclampsia (PE) is controversial [13, 14] . Leptin regulation is clinically relevant because circulating maternal plasma leptin concentrations are increased in (PE) compared to normal pregnant women [15, 16] . Thus, the role of leptin in uterine artery (UA) angiogenesis during normal pregnancy and diseases of pregnancy such as PE needs further study. The leptin receptor short form (LEPR S ) and active long form (LEPR L ) have been shown to be expressed in human vasculature [8, 9] , murine fetuses [17] , and in the human placenta [18, 19] . Leptin treatment of chick chorioallantoic membrane (CAMs), human fetal umbilical vein endothelial cells (HUVECs), aortic (bovine and porcine) endothelial cells, and adult microvascular corneal and human dermal microvascular cells increases angiogenesis (e.g., promoting proliferation and/or capillary-like structure formation) [8, 9] .
The follicular phase of the ovarian cycle and pregnancy are natural physiological states of elevated estrogen levels and uterine blood flow (UBF) [20, 21] mediated via the coordinated balance of uterine angiogenesis, vasodilation, and vascular remodeling [22] [23] [24] . During pregnancy, these uterine vascular adaptations lead to the rises in UBF which are required to provide for an adequate maternal-fetal vascular interface to meet the nutrient and oxygen demands of the rapidly growing fetus [21] . Using a preconception surgical model, we established a cohort of unilateral ovine pregnancies and demonstrated that rises in UBF as well as uterine vascular adaptations are seen only ipsilateral, but not contralateral, to the fetus and placental unit [25] [26] [27] . Additionally, we previously reported experimental analyses of the ex vivo uterine artery endothelium (UAendo) and uterine artery vascular smooth muscle (UAvsm) from pregnant versus nonpregnant ewes. In these studies we reported local uterine, but not systemic omental artery (OA) or renal artery (RA) effects of pregnancy-specific alterations, including elevations in specific levels of estrogen receptoralpha (ER-α) and ER-β, angiotensin II type-1 receptor expression, soluble and particulate guanylate cyclases, and pregnancy-enhanced activation of endothelial nitric oxide synthase [28] [29] [30] [31] [32] [33] [34] , demonstrating locally increased endothelial vasodilatory sensitivity to several specific hormones during gestation. Moreover, using a validated in vitro uterine artery endothelial cell (UAEC) pregnancy model, we noted pregnancy-specific estrogen, as well as estrogen metabolites, stimulated proliferative responses in pregnant UAECs (P-UAECs), but not nonpregnant (NP-UAECs) demonstrating angiogenic cellular programming is maintained in primary culture through multiple passages [35] . However, little is known concerning the local uterine versus systemic changes of UAendo and UAvsm expression of LEPR in pregnancy or in regulating UA angiogenesis.
Thus, we hypothesized that (1) ex vivo UAendo and UAvsm LEPR are locally elevated in pregnancy when compared to NP-UAendo (Luteal and Follicular) sheep; (2) in vitro leptin treatment will increase cell proliferation in cultured late P-UAECs more than NP-UAECs; and (3) expression of LEPR is maintained in vitro, and leptin activates the signal transducer and activator of transcription 3 (STAT3) signaling in P-UAECs and NP-UAECs relative to their angiogenic responses.
Materials and methods
For detailed methods see the online-only supplement at http:// biolreprod.org.
Tissue collection for ex vivo endo versus vascular smooth muscle leptin receptor using immunohistochemistry and western blotting analysis
All procedures were conducted with approval of the Institutional Animal Care and Use Committee of the University of Wisconsin-Madison, and School of Medicine and Public Health, Madison, Wisconsin, as previously described [35, 36] . For immunohistochemistry, nonpregnant (luteal, n = 4; follicular, n = 4) and pregnant (n = 4) sheep (120-130 days/gestation, term = 147 days) UA segments were collected and immediately fixed in paraformaldehyde followed by paraffin-embedding techniques as previously described [23] . The embedded UA tissues were sectioned (4 μm thick) for immunolocalization of the LEPR using an anti-LEPR (anti-LEPR) antibody. Mounted tissue sections were subsequently treated with avidin/biotin-based peroxidase (VECTASTAIN ABC system) as recommended by the manufacturer's instructions, followed by 3,3'diaminobenzidine (DAB Peroxidase Substrate) treatment and hematoxylin staining [37] .
In order to evaluate the local uterine-placental effects of gestation, our laboratory recently developed a preconception surgical unilateral model of gestation. This model restricts pregnancy to only one horn (gravid) throughout gestation allowing us to study local pregnancy-specific maternal-fetal vascular function and angiogenesis [25] [26] [27] . The control pregnant group comprised of sham operated (n = 15) and nonsurgical controls (n = 22). For the ex vivo western analysis of the LEPR in UA, OA, and RA that were obtained from synchronized nonpregnant (luteal; n = 8 and follicular; n = 8), unilateral pregnant (UA nongravid versus gravid sides; n = 15), and control bilateral pregnant sheep (120-130 days/gestation; n = 23) by reprobing the same western blots available from our previous work [26] . Western analysis were performed using methods we previously described [26, 30, 35, 38] and detection was performed using enhanced chemiluminescence (ECL) and HyperFilm ECL. Validation and loading controls for these western blots are described in these previous publications [26, 30] and the on line supplement.
Uterine artery endothelial cell isolation and experimental treatment with leptin
UAECs were isolated and fully validated from nonpregnant (luteal, n = 4; follicular, n = 4), and late pregnant (n = 4; 120-130 days/gestation) sheep as previously described and studied in culture at passage 4 UAECs [36, 38] . At ∼80% confluence, UAECs were transferred to 96-well plates at a density of 3.0 × 10 3 cells/well for corresponding treatments as designated by each experimental condition. Following 24 h of serum starvation NP-UAECs (Luteal and Follicular), P-UAECs were treated with vehicle (control) or seven doses of increasing concentrations of leptin (0.001-1000 ng/ml), and proliferative (mitogenesis) responses at 24 and 48 h were evaluated using the 5-Ethynyl-2-Deoxyuridine (EdU-labeled) Microplate Cell Proliferation assay technique (Invitrogen-Molecular probes, Eugene, OR) following the manufacturer's instructions.
Western blot analysis of cultured uterine artery endothelial cell leptin receptors and activated phospho-STAT3
Analysis of the LEPR protein expression and signaling [phospho-STAT3 (p-STAT3)] was evaluated on NP-UAECs (Luteal and Follicular; n = 4 and n = 4, respectively) and P-UAECs (n = 4) using anti-LEPR antibody capable of detecting both LEPR S and LEPR L of the LEPR, and anti-p-STAT3 and total STAT3 antibodies, respectively. For detecting activated p-STAT3, following 24 h of serum starvation fully validated passage 4 UAECs that were obtained from nonpregnant (Luteal and Follicular) and late pregnant sheep, which were allowed to reach ∼90 percent confluency in 6-well cell culture plates and then treated with vehicle (control) or leptin (1 ng/ml). Sample cells were collected at various time points (0-24 h) snap frozen and stored at -80 • C until analysis. Protein extraction and western analysis were performed using methods we previously described and validated [26, 35, 38] . Protein detection was performed using enhanced ECL and HyperFilm ECL with β-actin as loading control.
Statistical analysis
Differences between nonpregnant and late pregnant UA, OA and RA under ex vivo conditions, as well as between the in vitro nonpregnant UAECs and late pregnancy conditions were compared using one-way ANOVA (PRISM software version 7; GraphPad) with Bonferroni post hoc tests as required. Data are presented as means ± standard error of mean (SEM); P < 0.05 was chosen a priori as being significant.
RESULTS

Ex vivo uterine artery leptin receptor immunohistochemistry and western blot analysis
Immunohistochemical analysis of paraffin-embedded sections revealed that specific staining for the LEPR was localized in both UAendo and UAvsm of the nonpregnant luteal, nonpregnant follicular, and pregnant groups ( Figure 1A -C), when compared to the IgG negative control sections ( Figure 1D ). Contrary to our hypothesis, when compared to luteal phase controls and pregnant sections, UAendo and UAvsm LEPR immunolocalization staining qualitatively appeared to be highest in the follicular phase. Immunolocalization of LEPR in UAendo and UAvsm also appeared to be similar between luteal and pregnant groups.
For the western analysis of the ex vivo samples, only the LEPR L was observed. Western blot semiquantitative analysis confirmed these immunohistochemical observations revealing that when compared to UAendo luteal controls, the LEPR protein expression in the follicular phase was 3.5-fold higher ( Figure 1E ; P < 0.05). We also observed when comparing the UAendo protein levels of luteal controls, levels to all pregnancy-derived vessels including the unilateral nongravid group, unilateral gravid, and control pregnant which were respectively similar (P > 0.05), were 2.0-fold and 1-fold lower (P < 0.05). Similarly, for the UAvsm, LEPR protein expression showed that when compared to luteal controls, the LEPR in the follicular phase was 3.9-fold higher ( Figure 1F ; P < 0.05) and when compared to luteal controls, UAvsm LEPR protein levels in the nongravid group were similar (P > 0.05), while the gravid group was 2-fold lower (P < 0.05). However, in the UAvsm control pregnant group the LEPR protein levels were undetectable ( Figure 1F ).
Ex vivo systemic omental artery and renal artery leptin receptor western blot analysis
Western blot analysis revealed that when compared to luteal controls, the LEPR protein expression was not statistically different in, follicular, unilateral gravid, and pregnant OAendo, and OAvsm (Figure 2A and B, respectively). Although LEPR in RAendo were not altered (P > 0.05) by the ovarian cycle, pregnancy status (unilateral and control pregnant groups) appeared to collectively reduce (1.0fold lower) RAendo LEPR levels (P < 0.05) ( Figure 2C ). Protein expression analysis of the LEPR also revealed that when compared to luteal controls no statistical significant differences were observed in follicular, unilateral gravid, and pregnant RAvsm ( Figure 2D ).
Dose response effects of leptin treatment on luteal, follicular, and pregnant uterine artery endothelial cell proliferation
Because the 24 and 48 h mitogenesis responses were similar (P > 0.05) within each experimental group, these data were combined for presentation. Leptin treatment did not result in significant cell proliferation in luteal phase UAECs at all doses employed ( Figure 3A) . When compared to luteal control group, the follicular UAECs (Figure 3B ) showed a biphasic leptin-induced proliferative response (time and treatment effect, * P < 0.05), and a typical dose response was observed in the pregnant ( Figure 3C ) UAECs (Time and treatment effect, * P < 0.05). Follicular NP-UAECs appeared to be highly sensitive to the proliferative effects of even doses as low as 0.001 ng/ml, but responses at this dose were highly variable (P > 0.05) because only four of the six cell lines used demonstrated a proliferative response. At the subphysiological levels of leptin of 0.1 ng/ml when compared to that of physiological ranges in humans and sheep [11, 12, 39] , we observed maximum mitogenic responses (P < 0.05) in follicular NP-UAEC (1.70 ± 0.18 fold) and P-UAECs (1.50 ± 0.12 fold). As expected, luteal UAECs ( Figure 3A ) did not respond to the estradiol-17β (E 2 β) pregnancy-positive control treatment. Proliferation was however observed in both follicular and pregnant UAECs in response to E 2 β treatment when compared to the luteal control treatment ( Figure 3B and C).
In vitro leptin receptor expression and activated phospho-STAT3 signaling
We first determined if the greater proliferative responses to leptin observed in follicular and pregnant UAECs compared to luteal controls which were unresponsive, reflect changes in LEPR expression levels. Unlike the ex vivo samples described above, western blot analysis revealed that under in vitro basal culture conditions, both splice variants LEPR S and LEPR L proteins were expressed after passage 4 in luteal, follicular, and late pregnant UAECs at similar levels between groups ( Figure 4A ). Because the dramatically different mitogenic responses of the UAECs from the three physiologic conditions do not reflect changes in LEPR expression, we next evaluated this at the level of cell signaling sensitivity. Western blot analysis revealed that under in vitro culture conditions, p-STAT3 protein, a widely recognized marker to detect leptin signaling activation was expressed in luteal, follicular, and late pregnant UAECs. Protein expression of p-STAT3 was activated to a greater extent in the P-UAECs followed by follicular NP-UAECs when compared to the luteal UAECs which were mildly responsive ( Figure 4B ).
DISCUSSION
Leptin regulates important physiologic vascular, endocrine, and metabolic roles during the follicular phase of the ovarian cycle and normal pregnancy [16, 40, 41] . The key findings we report in the present study include the following: (1) LEPR in UAendo and UAvsm ex vivo were highest in the follicular phase of the ovarian cycle when compared to the luteal control and late pregnancy; (2) contrary to our hypothesis, LEPR was not upregulated ex vivo in UAendo and UAvsm in late pregnancy, but rather compared to follicular phase it was locally and substantially downregulated during pregnancy; (3) this was partly specific to the UAs since systemic LEPR were either unchanged (OAendo/vsm and RAvsm) or only modestly downregulated (RAendo) by pregnancy; (4) leptin initiated profound stimulatory effects on in vitro cell proliferation in both follicular and in late pregnancy, but not luteal UAECs; (5) under in vitro basal conditions, LEPR protein expression was similar in luteal, follicular, and late pregnant UAECs; however, leptin treatment resulted in higher activation of p-STAT3 during both follicular and late pregnancy conditions when compared to the luteal control.
Employing immunohistochemical analysis, we showed that the LEPR is expressed in both UAendo and UAvsm in the luteal and follicular phases of the ovarian cycle, and during late pregnancy. Others have shown LEPR expression in the ovary during the ovarian cycle [41, 42] , and in various vascular beds [7-9,43,44] (e.g., CAMs, HUVECs, aortic (bovine and porcine) endothelial cells, and adult microvascular corneal and human dermal microvascular cells); however, this is the first report of local LEPR expression in both UAendo and UAvsm during the ovarian cycle and late pregnancy in the sheep. Surprisingly, we noted that all of the immunohistochemically analyzed sections appeared to have greater density of LEPR in UAendo and UAvsm during the follicular phase when compared to luteal or late pregnancy conditions. We then used western analysis to investigate the semiquantitative expression profile of LEPR in UAendo and UAvsm again under ex vivo conditions. Consistent with the immunohistochemical analysis of LEPR, using western blotting we observed that when compared to the follicular phase UAendo and UAvsm, LEPR was locally and substantially downregulated in UAendo and UAvsm from luteal, and control pregnant ewes. Moreover, when we compared the LEPR in UAendo and UAvsm from the nongravid and gravid sides from the same pregnant animals LEPR levels were reduced more in the side ipsilateral versus contralateral to the fetus and placenta. Because the follicular phase is associated with elevations in the estrogen to progesterone ratio, UBF, and UA shear stress [26, [45] [46] [47] , we hypothesize that estrogen may be responsible for the observed upregulation of LEPR in the follicular UAs. The current 
observation of higher protein expression of LEPR in UAendo and
UAvsm during the follicular phase is in agreement with other studies showing an interaction between the effects of estrogen on leptin and the LEPR during the proliferative phase of the ovarian cycle in humans, as well as in studies employing ovariectomized rats [48] [49] [50] .
Our current data support a role for endogenous estrogen in regulating the LEPR and leptin levels in human cohorts and rats [48, 50] . For example, 8 weeks after ovariectomy rats showed a decrease in both leptin gene expression in subcutaneous and retroperitoneal white adipose tissue as well as plasma leptin levels. However, supplementation with 17β-estradiol returned leptin gene expression and plasma leptin levels in the ovarietomized group [48] . It is also possible that elevations in local shear forces transduced by the UAendo [26, 51] may help regulate the follicular rises in LEPR [52] . In addition, others have elucidated the role of leptin on the regulation of the LEPR, showing that 7 days of twice daily leptin administration reduced the LEPR mRNA expression at the level of the arcuate nucleus in obese (ob/ob) mice, which may be indicative of leptin regulation of its LEPR [53] . Using similar ex vivo preparations, we have reported that compared to luteal phase animals, the periovulatory follicular period is a dramatic period [20, 45] where other receptors in UAendo such as ER-α, ER-β [30, 32, 34] , angiotensin II type-1 [28, 33] , and atrial natriuretic peptide (ANP) [29] are elevated. Col-lectively, these data clearly suggest an important role of endogenous estrogen-mediated elevated LEPR in the preparation of the uterus for the increased UBF during periovulatory period. Pregnancy is also a state of elevated estrogen which in part maintains UBF [20, 21, 26, 27] ; however, progesterone from the feto-placental unit is also elevated systemically and locally [47, [54] [55] [56] . The current finding that unlike the follicular group, the UAendo and UAvsm LEPR was not higher, but lower in the late pregnant group and even lower ipsilateral versus contralateral to the gravid uterine horn, supports the theory of local downregulation of the LEPR by placental progesterone during pregnancy. In this regard, studies have demonstrated that in human endometrial tissue progesterone binding to the progesterone receptor decreases the mRNA expression of LEPR L [57] , indicating a direct negative regulatory role of progesterone on the LEPR.
In the current study, we also demonstrated that the changes in UAendo and UAvsm LEPR were partly specific to the UAs since systemic OAendo, OAvsm, and RAvsm LEPR were unchanged. These observations are consistent with specific uterine rather than systemic (OA and RA) regulation of other endo and vsm receptors (e.g., ER-α, ER-β, angiotensin II type-1, and ANP) we have studied [28] [29] [30] 32, 33] suggesting that local gravid endocrine changes regulate these receptors. There was one notable exception in that RAendo LEPR were modestly downregulated 1-fold similar to that observed for UAendo 1-fold when compared to luteal phase animals. During gestation renal plasma flow, renal blood flows (RBF) and glomerular filtration rate (GFR) are elevated especially in multiple fetal gestations [58] [59] [60] [61] . Leptin effects on renal vascular dynamics during gestation at this time are unclear [62] . However, LEPR are locally expressed in rat and mouse kidney suggesting peripheral regulatory roles on renal function [63, 64] . In studies performed on conscious normotensive or anesthetized lean rats treated with acute leptin, significant elevations in urine volume, and sodium excretion were observed; however, no significant changes in potassium excretion, RBF, and GFR were noted [65] [66] [67] . Additionally, leptin treatment of renal glomerular endothelial cells results in cell proliferation as well as the production of transforming growth factor-beta-1 [68] . Therefore, a reduction in RAendo LEPR in the present study is likely a physiological as well as an endocrine response to the already elevated levels of plasma leptin prior to near term.
We then investigated the role of leptin treatment on NP-UAECs and P-UAECs proliferation under standard culture conditions [35] . We demonstrated that leptin treatment resulted in no increase in UAEC proliferative responses during the luteal phase of the ovarian cycle. By contrast, there was a significant increase in cell proliferation in UAECs from the follicular phase revealing a biphasic dose response suggesting possibly receptor cooperativity [69, 70] of the various forms of the LEPR. However, late pregnancy showed a typical dose response when compared to vehicle control group.
To date, many different studies in various species including sheep and humans have shown that plasma leptin concentration increases as pregnancy progresses [11, 12, 18, [71] [72] [73] [74] [75] , with plasma leptin levels declining towards the end of pregnancy and transitioning to lactation [11, 12, 18, 76] . It is noteworthy that treating follicular and late pregnant UAECs with subphysiologic leptin doses [16, [77] [78] [79] as low as 0.1 ng/ml was able to bring about near maximum mitogenic responses demonstrating a very high degree of sensitivity under these culture conditions. We were surprised to see such a level of mitogenic sensitivity in the Follicular NP-UAECs and the P-UAEC remained intermediate, while, the Luteal NP-UAECs group were unresponsive to leptin. These data show that the sensitivity of mitogenic responses are seen at subphysiological levels, and this is more evident when considering that the equilibrium dissociation constant K D of leptin with both human and mouse LEPR has been shown to be around 0.23 ± 0.08 nM and 0.4 nM, respectively [80] . Another caveat is that our studies were performed under in vitro settings and our experimental conditions and thus UAECs were removed from the in vivo environment which may also explain the differences observed in sensitivity to leptin treatment especially in the Follicular NP-UAECs even though the Luteal NP-UAECs were completely unresponsive, but showed equal levels of LEPR by western analysis. Either way our responses were robust and at or below the physiologic ranges. These findings for cell proliferation are in agreement with key studies demonstrating the proliferative capacity and angiogenic nature of leptin treatment on a variety of endothelial cells, but in those studies it required orders of magnitude greater doses to achieve maximal proliferation [8, 9] . Thus, the present data suggest leptin may play angiogenic roles during the follicular phase to increase blood flow during the periovulatory period that is a state of high UBF. Similarly, the local angiogenic nature of leptin during late pregnancy would reflect that UAs are indeed sensitive and responsive perhaps to accommodate for the increases of UBF and placental blood flow to meet the demands of the rapidly growing fetus.
We further analyzed the state of the LEPR protein expression profile under in vitro conditions in passage 4 UAECs [32, 35, 36] . Surprisingly, under in vitro basal conditions, the LEPR S and LEPR L proteins were expressed at similar levels in luteal, follicular, and late pregnant UAECs. We had initially envisioned that after four passages [81] UAECs would retain the LEPR expression ex vivo profiles reported above for luteal, follicular, and late pregnancy which represent a snap shot of the in vivo setting [26, [28] [29] [30] 82] . Therefore, the higher expression of LEPR we observed in the follicular phase was lost before four passages in culture. Regardless, these current data clearly demonstrate that other elements of the downstream leptin postreceptor signaling pathway are responsible for the noted sensitivity differences in UAEC proliferation responses described herein. As reported by other laboratories, leptin-induced signaling, such as activation of the Janus tyrosine kinases (JAK/STAT), and the mitogen-activated protein kinase (MAPK) are likely to be responsible [8, 9, 70, 83, 84] .
Based on the proliferative capacity of follicular phase NP-UAECs and P-UAECs to respond to leptin treatment, we tested if leptin activation of classical canonical postreceptor signaling pathways were functional. Activation of such intracellular signaling pathways under the present culture conditions also demonstrated "proof-ofprinciple" that leptin actions are indeed being transduced intracellu-larly, thus explaining at least in part the cell proliferation responses observed. These data reported herein show that leptin treatment of follicular phase and P-UAECs indeed activated p-STAT3 in a biphasic fashion, exhibiting both an acute phase peak after 15 min for the follicular phase and after 1 h for P-UAEC followed by a secondary prolonged peak after 2 h for follicular phase and at 12 and 24 h for P-UAECs of leptin treatment. Interestingly, in response to leptin treatment, the follicular phase showed a modest increase in magnitude with a much longer biphasic sustained response which was quite different from the P-UAECs that showed a much higher magnitude response, however, with a more robust biphasic sustained response. Thus, we show that leptin treatment of follicular phase or P-UAECs activation of leptin signaling may differ greatly in terms of their phosphorylating responses and sustained magnitude depending on which of the two physiological conditions the UAECs are originally derived from. These patterns are consistent with those reported in HUVECs and in various cell types which also demonstrated a p-STAT3 biphasic response much like the follicular phase and P-UAECs group responses during the first 60 min of leptin treatment in the present study [9, 70, 83, 84] . However, to our knowledge we are the first group to present data showing a time course study including 12 and 24 h of p-STAT3 activation in follicular phase and P-UAECs in response to leptin treatment. In addition, our present data show that leptin treatment of luteal phase UAECs did not result in cell proliferation which is in agreement with our data showing no differences in p-STAT3 activation throughout the time course study. Thus, these data clearly show that the proliferative responses observed in our studies are indeed not as originally hypothesized fully pregnancy specific per se since follicular phase UAECs are very responsive to leptin treatment.
Thus, future studies are required relating to the role of how LEPR are coupled to and activate mitogenic pathways such as the JAK/STAT that is a major component of leptin signaling. However, STAT3 signaling per se may or may not be a key player for leptininduced UAEC angiogenesis, as there are a multitude of other wellknown signaling pathways that play key roles on EC angiogenesis. In this regard, the MAPK as well as the PI3K signaling pathways are candidates that warrant further investigation to elucidate the intracellular and molecular mechanisms driving enhanced UAEC proliferation and angiogenesis during the follicular phase and late pregnancy in sheep. For these future studies, the use of specific MAPK, PI3K, and STAT3 inhibitors on Follicular UAECs and P-UAECs with or without leptin treatment will address the role(s) of not only STAT3 on leptin-induced UAEC angiogenesis, but also extending studies to the MAPK and PI3K signaling pathways.
Perspectives
The present findings open an important area of research to understand leptin biology as it relates to the normal mechanisms driving local uterine vascular function and angiogenesis particularly in preparation for the increased UBF during the periovulatory period and subsequently to meet the demands of the growing fetus during normal pregnancy. Further, understanding the role of leptin on uterine vascular function may help decipher the in utero fetal programming mechanisms driving development of cardiovascular diseases and metabolic disorders in adult life. This is particularly significant in the ever-growing epidemic of pregnancies complicated by obesity and aberrant uteroplacental vascular development leading to insufficient blood flow induced IUGR.
